Commonwealth Equity Services LLC Acquires 28,395 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Commonwealth Equity Services LLC boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 190.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,341 shares of the biopharmaceutical company's stock after purchasing an additional 28,395 shares during the period. Commonwealth Equity Services LLC's holdings in ACADIA Pharmaceuticals were worth $795,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $47,000. KBC Group NV lifted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 2,044 shares during the period. Personal CFO Solutions LLC bought a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $224,000. PDT Partners LLC acquired a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at approximately $203,000. Finally, AlphaQuest LLC raised its holdings in ACADIA Pharmaceuticals by 283.8% during the 4th quarter. AlphaQuest LLC now owns 13,511 shares of the biopharmaceutical company's stock worth $248,000 after purchasing an additional 9,991 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.55. Following the sale, the executive vice president now directly owns 56,889 shares in the company, valued at $969,957.45. The trade was a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,433 shares of company stock valued at $187,319 in the last three months. Company insiders own 28.30% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ACAD. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Guggenheim lowered ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.93.

ACADIA Pharmaceuticals Trading Down 5.0 %

Shares of NASDAQ:ACAD traded down $0.77 during midday trading on Monday, reaching $14.61. The company had a trading volume of 2,167,515 shares, compared to its average volume of 1,839,301. The stock has a market cap of $2.44 billion, a P/E ratio of 18.73 and a beta of 0.54. The company's 50 day moving average price is $18.06 and its 200 day moving average price is $17.04. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $20.68.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.